Skip to main content

Fertility Preservation

0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Ferring Pharmaceuticals
Ferring PharmaceuticalsArgentina - Buenos Aires
1 program
Oxidative stressN/A1 trial
Active Trials
NCT05372549Completed179Est. Jan 2025
Ipsen
IpsenChina - Tianjin
1 program
TriptorelinPHASE_2_31 trial
Active Trials
NCT01160315Completed118Est. Oct 2015

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
IpsenTriptorelin
Ferring PharmaceuticalsOxidative stress

Clinical Trials (2)

Total enrollment: 297 patients across 2 trials

NCT01160315IpsenTriptorelin

Efficiency of Gonadotropin-releasing Hormone (GnRH) Agonist in Preventing Chemotherapy Induced Ovarian Failure

Start: Jul 2002Est. completion: Oct 2015118 patients
Phase 2/3Completed

Correlation of Oxidative Stress and Oocyte Quality in Fertility Preservation

Start: Jun 2022Est. completion: Jan 2025179 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.